Group items tagged

Pharmacy professionals to be included as key stakeholders in the implementation, delivery and evaluation of a wide range of genomic services, said the Royal Pharmaceutical Society (RPS). RPS's statement has been developed in collaboration with pharmacy organisations who have co-badged the report, such as the British Oncology Pharmacy Association, the UK Clinical Pharmacy Association, Association of Pharmacy Technicians and the College of Mental Health Pharmacy. It looks at current and future roles for pharmacy professionals in genomic medicine across many aspects of practice such as person-centred care and collaboration, professional practice, education, leadership, management and research. Pharmacists and pharmacy technicians in the UK have already established roles in the application of genomic medicine in some areas of practice, such as antimicrobial stewardship and infectious diseases, and the management of certain genetic conditions, such as cystic fibrosis. The society believes, the current role of pharmacy professionals in genomics can be expanded upon in the future to both lead and support many relevant aspects of genomic implementation. These are described across all healthcare sectors, within the Genome UK strategy produced by the UK Government, and within the implementation plans published in England, Scotland and Wales. Lead for Pharmacogenomics at RPS Sophie Harding said: "Pharmacy professionals are the gatekeepers of medication safety and efficacy across all areas of healthcare. They are skilled at interpreting complex scientific data and use evidence-based medicine to maximise the benefits of treatments for patients, whilst supporting shared decision-making with patients and the multidisciplinary team.

Pharmacy leaders from across the sector need to work together in order to have a stronger voice in the future of the healthcare system, Sir Hugh Taylor, chair of the UK Pharmacy Professional Leadership Advisory Board (UKPPLAB), has told Pharmacy Business. The establishment of this board in April 2024 was the principal recommendation of the UK Commission on Pharmacy Professional Leadership's report, published in February 2023. The report outlined that there is "an urgent need for the pharmacy professions to work collaboratively to deliver on their potential and, together, address a wide range of professional issues". "There's always been a measure of collaboration. And indeed, as we've begun our work, we've begun to unearth more examples of it, which is encouraging. But I think the conclusion that the UK Commission drew was that the fragmented nature of the professional leadership in pharmacy required something more concerted and organised in the form of the board," said Sir Hugh. Setup by the four UK chief pharmaceutical officers, the UKPPLAB is an independent public body, with the aim to enable greater collaboration across the pharmacy professional leadership bodies (PLBs) and specialist professional groups (SPGs), which are its constituent members.

At last Friday's Clinical Congress Conference, the NHSE Chief Pharmaceutical Officer for England at NHS England, David Webb, announced the upcoming launch of the Pharmacy Stakeholder Forum- an initiative led by NHS England aimed to improve pharmacy professional leadership and foster collaboration within the sector. Webb highlighted the forum's significance as a platform for driving transformative change in pharmacy leadership. "The aim is to deliver collaboration to develop a stronger and more united voice for pharmacy professionals," Webb emphasised. Highlighting the need to drive transformative change in pharmacy leadership, he underscored that "the overarching goal is to address key challenges facing the pharmacy profession and chart a course for future development and innovation." Scheduled to commence in June, the Pharmacy Stakeholder Forum will provide a space for diverse organisations and networks with a vested interest in pharmacy professional leadership to converge.

The Company Chemists Association (CCA)'s 'Prospectus for community pharmacy' has revealed that community pharmacies can release over 42 million appointments from general practice every year. In its prospect, the association calculated that community pharmacies could reduce hospital readmissions by 65,000 and administer an additional 10m routine vaccines annually. The prospectus sets out bold ideas and proposals regarding the future of community pharmacy. The association said: "Community pharmacies already work collaboratively with the NHS to ensure that patients can access care easily and safely. Whilst the sector has evolved considerably in recent years, the CCA proposes that pharmacies could do even more to directly tackle key problems for patients." CCA is concerned that without immediate action pharmacy closures will become increasingly common. "Fewer pharmacies will considerably diminish access to vital medicines and services, with the greatest impact on those in deprived communities."

Pharmacy Supervision Practice Group, an organisations from across the community pharmacy sector, who have come together to look into the future "supervision" in community pharmacy, have published their final report. Over the course of nine collaborative and positive workshop-style discussions the Supervision Practice Group aimed to provide recommendations to reframe legislation, regulation and professional standards and guidance to achieve a new vision for community pharmacy. The group have produced a report which makes several recommendations on the subjects of: * the legislation relating to "supervision"; * the temporary absence of the RP from the pharmacy; * delegation; * the preparation and assembly of medicines when the RP is not signed in. The group have provided recommendations on which the Department of and Social Care and the regulators can draft specifically worded revisions to legislation and regulatory standards. These specific legislative and regulatory changes that are proposed by government and regulators will be subject to a full consultation process.

The Pharmacy Supervision Practice Group consisting of members from AIMp, APTUK, CCA, NPA, PDA, PFNI and RPS held its fourth workshop to continue discussions on the future modelling of pharmacy practice. The ideas around 'supervision' shared by the organisation earlier formed the basis of the discussion during the workshop and helped to expand understanding of where there was consensus and disagreement. Examples of ideas explored during the workshop include: the extent to which a pharmacist should supervise the medicines assembly process, the purpose and extent to which a pharmacist might be absent from the pharmacy and how this might affect patient safety as well as the nature of whether fixed rules versus a broad framework were preferable for future practice. Chair of the group, Dr Michael Twigg, Associate Professor of Primary Care Pharmacy, University of East Anglia, said "Once again the sector bodies have come together in a collaborative and positive manner to explore the concept of 'supervision' in the context of current and future community pharmacy practice. This session provided an opportunity to constructively challenge assumptions and viewpoints within the group with the aim of moving the discussion forward." As part of the session, the DHSC, GPhC and PSNI gave an overview of the difference between legislation, regulation and guidance which was helpful to inform the group's thinking. Each of the organisations have been asked to use the conversation to refine the ideas presented in advance of the next workshop.

The General Pharmaceutical Council (GPhC) has unveiled its Carbon Net Zero Action Plan for sustainable pharmacy regulation, aiming to achieve carbon net zero by 2040. The action plan focuses on three main elements: setting an example, incorporating sustainability into regulatory standards, and fostering collaboration for sustainable pharmacy care. Roz Gittins, Chief Pharmacy Officer at the GPhC, emphasised the urgent need for pharmacy sector to embrace sustainable healthcare practices. "Climate change is a global emergency and has been declared the biggest threat to public health," she said, adding that it not only poses health risks but also amplifies existing health inequalities, with immediate consequences for patients, the public and health services. She highlighted that the GPhC is actively engaged in addressing climate change, both as an employer and regulator. "Our aim is to positively influence the pharmacy sector to embrace climate action and sustainable healthcare principles in line with our vision to have safe and effective pharmacy care at the heart of healthier communities," Gittins said.

Community Pharmacy England, Company Chemists Association, and the National Pharmacy Association have all expressed their disappointment at a recent press statement made by Dr Leyla Hannbeck, Chief Executive of the Association of Independent Multiple Pharmacies. The CPE, CCA and NPA refuted AIMp's claim that pharmacy bodies operate independently, emphasising the importance of employing various channels and strategies to shape public policy. "It makes sense to use a variety of channels and tactics to influence public policy," NPA, CPE and CCA said in a joint statement issued on Wednesday (August 13). "Limiting our work to just one Parliamentary channel would be naive and do a disservice to pharmacy owners." On Aug. 12, AIMp highlighted that a lack of cohesion was one of the contributing factors to the sector's difficulty in gaining wider attention. Dr. Hannbeck argued that it's counterproductive for each pharmacy organisation to maintain its own manifesto, essentially a lengthy wish-list that is often unrealistic and unattainable. "This can conveniently allow those in power to easily employ a divide-and-conquer strategy," she said.

The Department of Health in Northern Ireland has announced an immediate intervention worth over £5.3m in value, and a commitment to progress wider reform arrangements in collaboration with the Community Pharmacy NI (CPNI) to support pharmacies to deal with the ongoing pressure. The Minister and Department are 'very aware of the pressures facing community pharmacies'. They discussed the situation with CPNI representatives at a meeting last week. The scale of the unprecedented budgetary pressures and uncertainty currently facing the Department were spelt out. The Department said: "Notwithstanding these pressures, CPNI were informed that a support package for their sector was being finalised. This package includes immediate interventions worth over £5.3m in value, plus a commitment to progress wider reform arrangements in collaboration with CPNI." Recently, the CPNI highlighted that community pharmacists have issued a stark warning that shortages and skyrocketing prices of many medicines could result in pharmacies being unable to supply important prescription medicines to patients.

An executive director of Day Lewis and also board director and member of Association of Independent Multiple pharmacies (AIMp) Jay Patel highlighted the key issues and on ground challenges faced by the community pharmacies in a meeting hosted by Prime Minister Rishi Sunak and health secretary Steve Barclay in Downing Street on Saturday (January 7) to tackle the NHS pressure. In his interview with BBC, he said: "He (prime minister) was very engaging and trying to understand the key issues and practical challenges on the ground." Patel described the meeting atmosphere as 'collaborative and proactive', and said, "people were genuinely asked their options and there were listeners too." On BBC, answering to a question on 'how community pharmacies can alleviate the NHS pressure?', Patel said: "Pharmacies is the workplace for this. We have trust of our patients; we have high skilled workforce both clinically and professionally. One of the opportunities we have is working around the acute treat

The Royal Pharmaceutical Society (RPS) has published a consultation to review the 'Professional standards for the reporting, learning, sharing, taking action and review of incidents error reporting' in collaboration with Association of Pharmacy Technicians UK and Pharmacy Forum of Northern Ireland. The consultation is open from 21 April 2023 until 2 June 2023 and are due to be published in early 2024. All three professional leadership bodies are calling for contributions from anyone using the standards to ensure they are clear, current, relevant and fit for purpose. "The review affects all pharmacists, pharmacy technicians, trainees and members of the pharmacy team working in all sectors across the UK," RPS said. "The standards may also be of interest to the public, people who use pharmacy and healthcare services, healthcare and professionals working with pharmacy teams.

In a bid to bolster professional leadership within the pharmacy sector, the four government Chief Pharmaceutical Officers (CPhOs) have embarked on a significant initiative, forming the UK Pharmacy Professional Leadership Advisory Board (UKPPLAB). In a recent communication, all pharmacists and pharmacy technicians received confirmation of the board members selected by the CPhOs, alongside a note from the board's appointed chair, who was chosen collectively by the four CPhOs and reports directly to the CPhO for England. Over three years, the 21-member Board will implement recommendations from the UK Commission on Pharmacy Professional Leadership's report aimed to enhance professional fulfillment among pharmacists while simultaneously augmenting patient safety standards. This announcement also follows with the appointment of Sir Hugh Taylor as its Independent Chair and the appointment of Independent Expert Members who expressed his delight over the role's "potential to lead and support collaboration across the professions in the UK". However, the move has been met with cautious optimism from the Pharmacists' Defence Association (PDA), urging the new board to uphold transparency and openness to garner trust among pharmacists.

NHS England has announced a phased implementation for mandatory multi-sector rotations in the Foundation Pharmacist Training Programme, delaying the full rollout to the 2027/28 training year. Under the General Pharmaceutical Council's Standards for Initial Education and Training of Pharmacists (2021), multi-sector rotations - where trainees spend at least 13 weeks in a different pharmacy setting- were initially planned for all trainees starting in 2026/27. These rotations are designed to enhance pharmacists' adaptability, multi-professional collaboration, and ability to deliver person-centred care across healthcare systems. Acknowledging significant progress from pharmacy employers in developing these programmes, NHS England cited current workforce pressures as a key reason for introducing a phased approach. "We are mindful of the current pressures faced by pharmacy teams and the broader healthcare sector and greatly appreciate your continued commitment to delivering high-quality training. To support pharmacy teams in continuing to deliver high quality training, mandatory rotations will be delayed, and a phased approach will be implemented," David Webb, chief pharmaceutical officer for England and Samantha Illingworth, director of education quality and reform at NHS England, wrote in a letter to training programme providers.

May I be one of the last people to wish you a 'Happy New Year' The new year is traditionally a time to reflect on the year past and look forward to the new year and all the joys and challenges it will bring, possibly by making a resolution. However, the statistics do not bode well for your resolution lasting. Whether it is to improve your health/lose weight (the no.1 resolution) or performing better at work (3%), the Forbes Health/One Poll survey found that the average resolution lasts just 3.74 months. Only 8% of respondents tend to stick with their goals for one month, while 22% last two months, 22% last three months and 13% last four months. So that's nearly 2/3 gone by 4 months. I only mention this because at the tail end of 2024, I thought Pharmacy, or more specifically Pharmacy Representative bodies had taken an early resolution and decided to get along. I am passionate about Collaboration and am a member of the Institute for Collaborative Working (ICW) and have spoken on the topic at conferences, the Pharmacy Show, etc, and also written in this very magazine on the subject (see Volume 20 March 2024). I have also been pretty dismayed at the lack of collaboration at a representation level leading to headlines such as "Don't underestimate the power of unity" and "Sector disagreement over call for unity" coupled with some 99% of participating pharmacy owners saying they were willing to limit their services unless funding is improved.

Leaders from across the pharmacy sector and trade bodies dwelled on the challenges faced by the pharmacists at the Sigma Conference held on Sunday (2 October). "If the cost of carrying out regulation is higher than the benefits, it's time for all the bodies to sit together and talk on what can be adjusted accordingly," said Salim Jetha, Chairman, Avicenna. Jetha highlighted the challenges faced by the independent pharmacy and also raised the concern about the 'level playing field' for pharmacists compared to GPs. He said: "GPs get paid for energy cost, premises cost, the staffing cost. We don't get paid for that. So don't be misled by saying we are being exactly the same. Yes, on paper we are, but in reality we are not. I think also the rules of engagement are different." He called for better collaboration with GPs, and urged PSNC and other trade bodies to ensure a level playing field. Janet Morrison, CEO, Pharmaceutical Services Negotiating Committee(PSNC), warned that the pressure in the sector is building up to a 'breaking point'.

The Royal Pharmaceutical Society's (RPS) second roundtable on workforce wellbeing resulted in a series of collaborative actions to address pharmacy professionals' mental health and wellbeing challenges. The roundtable brought together key stakeholders from the pharmacy sector, including organisations like the General Pharmaceutical Council (GPhC), Community Pharmacy England (CPE), the National Pharmacy Association (NPA), and the profession's independent charity Pharmacist Support (PS). A report detailing the outcomes of the meeting was published on Friday, highlighting the key areas of discussion and the agreed-upon actions by the participants. During the roundtable, participants discussed the importance of understanding the workforce demographics, both nationally and locally, and using data to address wellbeing issues effectively. They also emphasised the need for using supportive standards set by the General Pharmaceutical Council (GPhC) and the Care Quality Commission (CQC) quality statement to support and empower pharmacists' wellbeing positively.

The Royal Pharmaceutical Society (RPS) and Pharmacist Support have announced a formal agreement aimed at enhancing collaboration to better support RPS members and increase the impact of the charity. This partnership comes after years of working closely together, and formalising it will allow both organisations to reach a wider audience and focus on supporting the wellbeing of pharmacy professionals. The aim of the partnership is to establish a visible link between the professional body and the independent charity to increase awareness about the two organisations for greater focus on the support within the sector. Along with this, the key objectives also include identifying fundraising opportunities for Pharmacist Support, and collaborating on specific wellbeing projects.

Boots UK has agreed to grant a five per cent pay increase to its pharmacists following a collaborative agreement with the Pharmacists' Defence Association (PDA). This raise acknowledges the unique market conditions faced by pharmacists in the community pharmacy sector, Boots UK and PDA said in a joint statement on Oct. 9. According to the statement, the pay increase applies to all pharmacists within the PDA Union's bargaining unit, except for those who joined or received a pay raise after August 2023. Moreover, trainee pharmacists or those not meeting performance standards are not eligible for the raise. Additionally, pharmacists and store managers will receive a pro-rata, one-time non-consolidated payment of £750 in August 2024. This payment serves as recognition for their dedication to establishing and providing new core and advanced NHS services, particularly in light of the substantial changes anticipated in the upcoming year, the joint statement said. The services include new medicines, hypertension, contraception, and common conditions services in England, the clinical community pharmacy service in Wales, and the Pharmacy First services in Scotland and Northern Ireland.

The Galien Foundation recently announced the winners of the 2024 Prix Galien UK Awards, with the University of Oxford receiving accolades for its groundbreaking contributions to public sector innovation through the PRINCIPLE and PANORAMIC Trials. These trials, spearheaded by Oxford's team of experts, have set a new standard for scientific innovation aimed at improving global health outcomes. Led by University of Oxford, the PRINCIPLE and PANORAMIC Trials epitomize a remarkable collaboration aimed at combating the COVID-19 pandemic.

The UK government has announced the launch of a new joint public-private investment programme aimed at accelerating patient access to cutting-edge treatments, enhancing clinical trials, and bolstering the country's medicines manufacturing capabilities. Supported by up to £400 million of investment, the Voluntary Scheme for Branded Medicine Pricing, Access and Growth (VPAG) Investment Programme is set to inject significant resources into the UK's health and life sciences sector over the next five years. Believed to be the world's first major public-private collaboration of this scale globally, the VPAG Investment Programme is designed to boost economic growth and the global competitiveness of the UK's life sciences sector. It aims to strengthen the NHS by supporting innovative research and creating 18 new clinical trial hubs to fast-track the development of new medicines for patients. The programme will also streamline processes to ensure the rapid transition of new treatments from labs to wards, providing patients with faster access to cutting-edge treatments. Health and Social Care Secretary Wes Streeting hailed this private investment as "a significant vote of confidence in the UK" highlighting that it will fast-track the next generation of treatments to NHS patients.